Arcutis to Present at the Cowen 40th Annual Health Care Conference
February 19 2020 - 8:30AM
Arcutis Biotherapeutics, Inc. (Nasdaq: ARQT), a late-stage
biopharmaceutical company focused on developing and commercializing
treatments for unmet needs in immune-mediated dermatological
diseases and conditions, or immuno-dermatology, today announced
that President and CEO Frank Watanabe will present at the Cowen
40th Annual Health Care Conference in Boston on Tuesday, March 3,
2020 at 10:00 a.m. ET.
The presentation will be webcast and may be
accessed at the “Events & Presentations” section of the
Company’s website at
https://investors.arcutis.com/events-and-presentations. Arcutis
will maintain an archived replay of the webcast on its website for
30 days after the conference.
About Arcutis - Bioscience, applied to the
skin.
Arcutis is a late-stage biopharmaceutical
company focused on developing and commercializing treatments for
unmet needs in immune-mediated dermatological diseases and
conditions, or immuno-dermatology. Arcutis exploits recent
innovations in inflammation and immunology to develop potential
best-in-class therapies against validated biological targets,
leveraging our deep development, formulation and commercialization
expertise to bring to market novel dermatology treatments, while
maximizing our probability of technical success and financial
resources. Arcutis is currently developing three novel compounds
(topical roflumilast cream (ARQ-151), topical roflumilast foam
(ARQ-154) and ARQ-252) for multiple indications, including
psoriasis, atopic dermatitis, seborrheic dermatitis and eczema. For
more information, please visit www.arcutis.com or follow the
Company on LinkedIn.
Contact:John W. SmitherChief
Financial Officerjsmither@arcutis.com
Investors and Media:Derek Cole,
PresidentInvestor Relations Advisory
Solutions720.785.4497derek.cole@IRadvisory.com
Arcutis Biotherapeutics (NASDAQ:ARQT)
Historical Stock Chart
From Mar 2024 to Apr 2024
Arcutis Biotherapeutics (NASDAQ:ARQT)
Historical Stock Chart
From Apr 2023 to Apr 2024